glp 1 kidney protection Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic disease: an approach for the nephrologist Potential kidney-protective and other effects
Description
cite Evidence and approval: Several injectables are FDA-approved specifically for chronic weight management after large trials
It includes an increasing aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity
The mean duration of diabetes was 4 years
In particular, the SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial evidenced neutral effects of saxagliptin in terms of cardiovascular outcomes, but an increased risk of hospitalization for HF, especially in patients with high levels of natriuretic peptides, previous HF, or chronic kidney disease [148]
Gastric Bypass NSAIDs and steroids may be restricted because of ulcer risk
New England Journal of Medicine , 384 (18), 17191730
